The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
Lol you were right last time Chris but would love to know where your source gets this from!!
Also I wouldn’t trust accuracy of LinkedIn too much! Just because someone is a senior scientist doesn’t mean there is a junior below them always. Could be recognition of the skill and calibre of expertise required for complex technical roles. Also the company has restructured and we don’t know what the reporting lines are like now.
Some marketing of MD going out
https://www.linkedin.com/posts/fusion-antibodies-plc_fusion-antibodies-mammalian-display-activity-7188501312152494080-1KbS?utm_source=share&utm_medium=member_ios
Look at the detail of it - responsible for the commercialisation of Optimal and Mammalian Display. The NCI validation must be going well if they’re pushing the go button on roles for commercialisation
Their LinkedIn page suggests a couple of staff have been rehired. Regardless, it’s quite positive to see that staff want to return to the company after being made redundant. Suggests a good culture and if it was me I wouldn’t want to go back unless they were confident they won’t be in a similar position as before and they had faith in the position of the business!
They’re not taking contracts with zero revenue - they clearly stated they will receive fees for their services on that RNS yesterday, just that they’re not material. This has been clear from start that Optiphage is a lower price point service - they’ve been clever here in that they’ve managed to secure long stream revenue potential from a more attractive lower price service as part of diversification, which is evidently working.
Totally agree - this is nuts response from market. Large player in diagnostics sector - potential to see returns much quicker than if this was clinical antibody too as they’ll not need to go through trials etc! Only can be seen as positive!
OptiPhageTM, a phage display based version of the same DNA library. OptiPhageTM uses the same DNA sequences as OptiMAL® but packages them into a more commonly used Phage display format. Only smaller antibody fragments can be screened in this way, compared to whole antibodies via OptiMAL®, but it can be run at a lower price point for the customer. The Directors believe that the provision of OptiPhageTM provides the Company with an ability to protect the premium pricing of the OptiMAL® programme whilst meeting budgetary constraints of its customers. It may also be the platform of choice for those wanting antibody fragments as their end product; and